Axsome Therapeutics (US.AXSM)
Capital Allocation Audit · Period: 2013 – 2026
Key Metrics
US.AXSM · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 100.6% | → |
| ROE | -118.2% | ↓ |
| Cash Conversion | - | → |
| D/E Ratio | 4.03 | → |
| Gross Margin | 92.3% | → |
US.AXSM (Axsome Therapeutics) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ----------------------------- FCF Conversion 100.6% → ROE -118.2% ↓ Cash Conversion - → D/E Ratio 4.03 → Gross Margin 92.3% →
Key Metrics
US.AXSM (Axsome Therapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY-----------------------------FCF Conversion 100.6% →ROE -118.2% ↓Cash Conversion - →D/E Ratio 4.03 →Gross Margin 92.3% →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies